Why Novo Nordisk stock fell 7% after a telehealth startup's announcement
Novo Nordisk's stock dove 7% on Thursday just after an announcement from a key competitor.
Novo Nordisk shares rebound as FDA targets illegal drug copies
Shares in Danish drugmaker Novo Nordisk gained 4.7% in early trading on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.
Hims & Hers launches compounded semaglutide pill as lower-cost weight loss option
Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an alternative to Novo Nordisk (NYSE:NVO)'s Wegovy. The oral treatment uses the same active ingredient as Wegovy but is formulated to improve digestion and absorption, eliminating the need for injections.
Novo Nordisk: A Game Of Price Vs. Volume
Novo Nordisk A/S maintains a Buy rating despite recent share declines and challenging FY2026 guidance. NVO faces persistent pricing pressures, margin compression, and market share loss but is betting on volume growth and pipeline expansion. NVO stock valuation is historically low at a 13.8 P/E, offering a favorable entry point for long-term investors anticipating post-2026 recovery.
Novo Nordisk Q4: Slumping Due To Weak Guidance
Novo Nordisk A/S shares dropped ~20% after issuing weaker-than-expected 2026 guidance despite strong 2025 obesity drug growth. NVO's 2025 revenue rose 10% at constant currency rates, but margin compression and higher costs left net profit flat; the obesity franchise grew 31%. 2026 guidance forecasts ~9% constant currency revenue and profit decline, driven by U.S. drug pricing pressures and patent expirations.
Novo to launch Ozempic pill for diabetes in second quarter of this year
Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year.
Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade)
Novo Nordisk A/S faces disappointing 2026 guidance, projecting a 5–13% revenue and operating profit decline despite Wegovy pill adoption. Margin pressure arises as the oral Wegovy pill is costlier to produce and priced lower than injectables, compressing profitability even amid surging demand. US pricing pressure, currency headwinds, and competition from Eli Lilly compound risks, pushing NVO's FWD price/FCF multiple to 33x amid deteriorating fundamentals.
Novo Nordisk Stock Sinks on Weak Sales Forecast
Novo Nordisk A/S (NYSE:NVO) stock is extending last session's 14.6% slide, down 3.7% to trade at $48.44 at last glance.
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
Novo Nordisk plunge wipes $50 billion off obesity drug giant
Novo Nordisk shares tumbled 16% on Wednesday, wiping off around $50 billion from the Wegovy maker's market capitalization after it warned on Tuesday its sales and profits would fall in 2026.
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
Having pre-announced earnings a day earlier, Novo Nordisk CEO Mike Doustdar, faced the European media Wednesday morning and gave a series of downbeat assessments of the company's prospects in 2026.
